American Society of Clinical Oncology

SHERPA: White

People

  1. Carrasquillo
    Carrasquillo
  2. Morris
    Morris
  3. Pandit-Taskar
    Pandit-Taskar
  4. Scher
    Scher
  5. Rathkopf
    Rathkopf
  6. Slovin
    Slovin
  7. O'Donoghue
    O'Donoghue
  8. Solit
    Solit
  9. Cheal
    Cheal
  10. Gonen
    Gonen

Groups

  1. Department of Medicine (6)
  2. GSK Faculty (6)
  3. Genitourinary Oncology Service (6)
  4. Molecular Imaging and Therapy Service (6)
  5. Molecular Pharmacology and Chemistry Program Faculty (6)
  6. Radiology, Department of (6)
  7. Sloan Kettering Institute Faculty (6)
  8. Solid Tumor Oncology Division (6)
  9. Hematologic Malignancies, Division of (5)
  10. Medical Physics (4)
Search Within
  1. "Dana Rathkopf"
  2. "Jorge Carrasquillo"
Formats
  1. Meeting Abstract (5)
  2. Journal Article (1)
Groups
  1. Department of Medicine (6)
  2. GSK Faculty (6)
  3. Genitourinary Oncology Service (6)
  4. Molecular Imaging and Therapy Service (6)
  5. Molecular Pharmacology and Chemistry Program Faculty (6)
  6. Radiology, Department of (6)

More Groups

People
  1. Dana Rathkopf (6)
  2. Howard Scher (6)
  3. Jorge Carrasquillo (6)
  4. Michael Morris (6)
  5. Neeta Pandit-Taskar (6)
  6. Steven Larson (6)

More People

Years
  1. 2015 (2)
  2. 2010 (1)
  3. 2009 (2)
  4. 2008 (1)
Publications
  1. Journal of Clinical Oncology (6)

Results (6)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Tumor-directed PET imaging of metastases in metastatic castration-resistant prostate cancer (mCRPC) using Zr-89 labeled antiprostate-specific membrane antigen (PSMA) antibody J591
    Meeting Abstract

    Feldman, J. L.; Morris, M. J.; Martinez, D. F.; Tagawa, S. T.; Nanus, D. M.; Solomon, S. B.; Carrasquillo, J. A.; Reuter, V. E.; Lewis, J. S.; O'Donoghue, J. A.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Tumor-directed PET imaging of metastases in metastatic castration-resistant prostate cancer (mCRPC) using Zr-89 labeled antiprostate-specific membrane antigen (PSMA) antibody J591
    Meeting Abstract

    Feldman, J. L.; Morris, M. J.; Tagawa, S. T.; Nanus, D. M.; Solomon, S. B.; Carrasquillo, J. A.; Reuter, V. E.; Lewis, J. S.; O'Donoghue, J. A.; Martinez, D. F.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase I pharmacokinetic (PK) and biodistribution study of radium-223 chloride in patients with castration resistant prostate cancer (CRPC) metastatic to bone
    Meeting Abstract

    Carrasquillo, J. A.; O'Donoghue, J. A.; Pandit-Taskar, N.; Rathkopf, D. E.; Aksnes, A.; Viner, C. L.; Hong, C. T.; Larson, S. M.; Scher, H. I.; Morris, M. J.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Phase I/II study of docetaxel and (153)Sm for castrate metastatic prostate cancer (CMPC): Summary of dose-escalation cohorts and first report on the expansion cohort
    Meeting Abstract

    Morris, M. J.; Pandit-Taskar, N.; Stephenson, R. D.; Hong, C.; Slovin, S. F.; Rathkopf, D.; Solit, D.; Carrasquillo, J.; Larson, S.; Scher, H. I.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer
    Journal Article

    Morris, M. J.; Pandit-Taskar, N.; Carrasquillo, J.; Divgi, C. R.; Slovin, S.; Kelly, W. K.; Rathkopf, D.; Gignac, G. A.; Solit, D.; Schwartz, L.; more...
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Phase I study of docetaxel (Tax) and (153)Sm repetitively administered for castrate metastatic prostate cancer (CMPC)
    Meeting Abstract

    Morris, M. J.; Pandit-Taskar, N.; Stephenson, R. D.; Hong, C.; Slovin, S. F.; Solit, D.; Rathkopf, D. E.; Carrasquillo, J. A.; Larson, S. M.; Scher, H. I.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save